Cellular and Humoral Immune Responses in Mice Immunized with Vaccinia Virus Expressing the SARS-CoV-2 Spike Protein
Open Access
- 10 May 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 206 (11) , 2596-2604
Abstract
The COVID-19 pandemic is a global health emergency, and the development of a successful vaccine will ultimately be required to prevent the continued spread and seasonal recurrence of this disease within the human population. However, very little is known about either the quality of the adaptive immune response or the viral Ag targets that will be necessary to prevent the spread of the infection. In this study, we generated recombinant Vaccinia virus expressing the full-length spike protein from SARS-CoV-2 (VacV-S) to evaluate the cellular and humoral immune response mounted against this viral Ag in mice. Both CD8+ and CD4+ T cells specific to the SARS-CoV-2 spike protein underwent robust expansion, contraction, and persisted for at least 40 d following a single immunization with VacV-S. Vaccination also caused the rapid emergence of spike-specific IgG-neutralizing Abs. Interestingly, both the cellular and humoral immune responses strongly targeted the S1 domain of spike following VacV-S immunization. Notably, immunization with VacV-expressing spike conjugated to the MHC class II invariant chain, a strategy previously reported by us and others to enhance the immunogenicity of antigenic peptides, did not promote stronger spike-specific T cell or Ab responses in vivo. Overall, these findings demonstrate that an immunization approach using VacV or attenuated versions of VacV expressing the native, full-length SARS-CoV-2 spike protein could be used for further vaccine development to prevent the spread of COVID-19.Keywords
Funding Information
- HHS | NIH | National Institute of Allergy and Infectious Diseases (R01-AI132404)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (R01-AI145835)
- HHS | NIH | NIH Office of the Director (8P51-OD011092)
This publication has 58 references indexed in Scilit:
- Antiviral Immunity following Smallpox Virus Infection: a Case-Control StudyJournal of Virology, 2010
- T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected MiceJournal of Virology, 2010
- Lethal Infection of K18- hACE2 Mice Infected with Severe Acute Respiratory Syndrome CoronavirusJournal of Virology, 2007
- The persistence of humoral and cellular immunities more than three decades after smallpox vaccinationClinical Microbiology and Infection, 2007
- SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virusVaccine, 2007
- Immunity and immunological memory following smallpox vaccinationImmunological Reviews, 2006
- The history of the smallpox vaccineJournal of Infection, 2006
- Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccinesJournal of Experimental Medicine, 2004
- Duration of antiviral immunity after smallpox vaccinationNature Medicine, 2003
- Construction of a Novel Virus That Targets HIV-1-Infected Cells and Controls HIV-1 InfectionCell, 1997